Therapeutic efficacy of ranitidine bismuth citrate with clarithromycin for seven days in the eradication of Helicobacter pylori in Brazilian peptic ulcer patients
Keywords:
Helicobacter pylori, Eradication, Peptic ulcer treatment, Ranitidine-bismuth, Clarithromycin therapeutic useAbstract
CONTEXT: The curative treatment of peptic ulcer is made available nowadays through the eradication of the bacterium Helicobacter pylori, which is associated with it, but the best therapeutic regimen is yet to be determined. OBJECTIVE: To assess the efficacy of a therapeutic regimen with 400 mg ranitidine bismuth citrate associated with 500 mg clarithromycin given twice a day for seven days in a cohort of Brazilian patients with peptic ulcer. TYPE OF STUDY: Cross-sectional study. SETTING: Tertiary-care hospital. PATIENTS: One hundred and twenty nine outpatients, with active or healed peptic ulcers infected by Helicobacter pylori, diagnosed via endoscopy with confirmation via the urease test and histological examination, who had never undergone a regimen for the eradication of the bacterium. PROCEDURE: Administration of 400 mg ranitidine-bismuth and 500 mg clarithromycin twice a day, for seven days. MAIN MEASUREMENTS: Efficacy of the treatment, with a check on the cure done via another endoscopy eight weeks after drug administration. The eradication of the bacterium was determined via the urease test and histological examination. Patients who were negative for both were considered to be cured. RESULTS: Eight patients failed to complete the study. The eradication rate according to intention to treat was 81% (104/129) and per protocol was 86% (104/121). CONCLUSION: The bismuth ranitidine compound associated with clarithromycin used for one week was shown to be a simple, effective and well-tolerated therapeutic regimen for the eradication of Helicobacter pylori.
Downloads
References
Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984;1:1311-5.
Mégraud F, Lamouliatte H. Helicobacter pylori and duodenal ulcer. Evidence suggesting causation. Dig Dis Sci 1992;37(5):769-72.
An international association between Helicobacter pylori infec- tion and gastric cancer. The EUROGAST Study Group. Lan- cet 1993;341(8857):1359-62.
Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long term recurrence of gas- tric or duodenal ulcer. A randomized controlled study. Ann In- tern Med 1992;116(9):705-8.
Patchett S, Beattie S, Leen E, Keane C, O’Morain C. Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol 1992;87(1):24-7.
Rai RR, Nighwawan S, Bhargava N, Nepalia S, Pokharna DS.. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992;87(12):1716-27.
de Boer WA, Driessen WM, Potters VP, Tytgat GN. Randomized study comparing 1 with 2 weeks for quadruple therapy for eradi- cating of Helicobacter pylori. Am J Gastroenterol 1994;89(11):1993-7.
Dixon JS. Helicobacter pylori eradication: unravelling the facts. Scand J Gastroenterol 1995;212(suppl 30):48-62.
Ciociola AA, Webb DD, Turner K. Dual and triple therapy regimens of antisecretory agents and antibiotics for the eradica- tion of Helicobacter pylori: an overview. Scand J Gastroenterol 1996;218(suppl 31):3-9.
Pounder RE, Bailey R, Louw JA, et al. Ranitidine bismuth citrate with clarithromycin for the eradication of Helicobacter pylori. Gut 1995;37(Suppl 1):A42 (Abstract).
Bardhan KD, Dallaire C, Eisold H, Duggan AE. Ranitidine bismuth citrate with clarithromycin for the treatment of duo- denal ulcer. Gut 1997;41(2):181-6.
Sakita, T. Endoscopy in diagnosis of early gastric cancer. Clin Gastroenterol 1973;2:345-60.
Axon AT, Ireland A, Smith MJ, Rooprams PD. Ranitidine bis- muth citrate and clarithromycin twice daily in the eradication of Helicobacter pylori. Aliment Pharmacol Ther 1997;11(1):81-7.
Dobrilla G, Di Matteo G, Dodero M, et al. Ranitidine bis- muth citrate with either clarithromycin 1 g/day or 1.5 g/day is equally effective in the eradication of H. pylori and healing of duodenal ulcer. Aliment Pharmacol Ther 1998; 12(1):63-8.
Lanza FL, Sontag SJ, Ciociola AA, Sykes DL, Health A, McSorley DJ. Ranitidine bismuth citrate plus clarithromycin: a dual therapy regimen for patients with duodenal ulcer. Helicobacter 1998;3(3):212-21.
Savarino V, Zentilin P, Bisso G, et al. Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and
metronidazole in the eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1999;13: 43-7.
Bazzoli F, Bianchi-Porro GB, Fiocca R, et al Efficacy of omeprazole plus amoxicillin or amoxicillin plus clarithromycin for one week or two weeks in the Helicobacter pylori eradication in patients with duodenal ulcer. Gut 2000;47(suppl 1):A79.
Fock KM, Chelvam P, Lim SG. Triple therapy in the eradica- tion of Helicobacter pylori in patients with duodenal ulcer dis- ease: results of a multicenter study in South-East Asia. South- East Asia Multicenter Study Group. Aliment Pharmacol Ther 2000;14(2):225-31.
Lind T, Mégraud F, Unge P, et al. The MACH 2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999;116(2):248-53.
Pare P, Romaozinho J, Bardhan KD, et al. Ranitidine bismuth citrate is more effective than omeprazole in the eradication of Helicobacter pylori when co-prescribed with clarithromycin. Gastroenterology 1997;112:A251(abstract).
Harris A. Current regimens for treatment of Helicobacter pylori infection. Br Med Bull 1998;54(1):195-205.
Silva FM, Zaterka S, Eisig JN, Chehter EZ, Chinzon D, Laudanna AA. Factors affecting Helicobacter pylori eradication using a seven-day triple therapy with a proton pump inhibitor, tinidazole and clarithromycin, in Brazilian patients with peptic ulcer. Rev Hosp Clin Fac Med São Paulo 2001;56(1):11-6.
